Identification of STX-721, an EGFR exon 20 mutant inhibitor with superior selectivity and a potential best-in-class profile

Tagrisso (osimertinib) - AstraZeneca

Exkivity (mobocertinib) - Takeda

sunvozertinib (DZD9008) - Dizal Pharma

tuxobertinib (BDTX-189) - Black Diamond Therap

Pozenveo (poziotinib) - Spectrum Pharma, Luye Group

zipalertinib (CLN-081) - Cullinan Oncology, Otsuka

STX-721 - Scorpion Therap

https://cm.eortc.org/cmportal/searchable/ena2022/config/normal#!abstractdetails/0000928620

R. Pagliarini1; B.C. Milgram1; D.R. Borrelli1; N. Brooijmans1; M.R. Huff1; T. Ito1; P. Jonsson1; B. Ladd1; E. O'Hearn1; W. Wang1; P. Kuzmic2; J. Bellier3; A.N. Hata3; A. Guzman-Perez1; D.D. Stuart1

Sep 3, 2022